DC Field | Value | Language |
dc.contributor.author | Tihon, Beatricie-Marinela | |
dc.date.accessioned | 2024-10-28T12:50:28Z | |
dc.date.accessioned | 2024-11-18T21:30:36Z | |
dc.date.available | 2024-10-28T12:50:28Z | |
dc.date.available | 2024-11-18T21:30:36Z | |
dc.date.issued | 2024 | |
dc.identifier.citation | TIHON, Beatricie-Marinela. The role of estrogens in cardiovascular disease. In: MedEspera: the 10th Intern. Medical Congress for Stud. and Young Doctors, 24-27 April 2024: abstract book. Chișinău, 2024, p. 334. ISBN 978-9975-3544-2-4. | en_US |
dc.identifier.isbn | 978-9975-3544-2-4 | |
dc.identifier.uri | https://medespera.md/en/books?page=10 | |
dc.identifier.uri | http://repository.usmf.md/handle/20.500.12710/28742 | |
dc.description | Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu”, Chişinău, Republica Moldova | en_US |
dc.description.abstract | Introduction. Epidemiological studies have shown that 17beta-estradiol (E2) levels are inversely
associated with cardiovascular disease (CVD) events in post-menopausal women. This indicates
that estrogens have a possible implication in CVD pathogenesis, through their genomic and nongenomic mechanisms of action.
Aim of study. Highlighting the role of estrogens and estrogen receptors in cardiovascular disease
pathophysiology.
Methods and materials. Publications from the last 5 years, from specialized journals of the
PubMed databases, were selected and analyzed using the following keywords: estrogen, estrogen
receptors, genomic and non-genomic mechanisms, cardiovascular disease.
Results. Estrogens, through their specific receptors (ERα, ERβ and GPR30s), displayed prominent
effects on cardiovascular disease pathogenesis. Evidence suggests their role in the management of
systemic and pulmonary arterial hypertension, protecting against atherogenesis, ischemia-reperfusion injury, and safeguarding against heart failure with either reduced or preserved ejection
fraction (EF). The specific mechanisms of ERα include reducing sympathetic outflow and
endothelial dysfunction, decreasing fibrosis and pulmonary vascular remodeling, preserving EF,
and enhancing systolic function. ERβ performs by decreasing vasoconstriction, vascular resistance
and hypertrophy, mitigating fibrosis and inflammation, reducing apoptosis and preserving
mitochondrial integrity, promoting cardiac angiogenesis and normalizing hemodynamic
parameters. GPR30s mechanisms of action encompass relaxation of vascular smooth muscle,
influence on nitric oxide synthesis, calcium level regulation, modulating cholesterol levels, and
minimizing both inflammation and reactive oxygen species production.
Conclusion. Estrogens displayed a possible involvement in managing cardiovascular disease, by
reducing both the progression and severity of numerous cardiovascular pathologies through
various genomic and non-genomic mechanisms of action. Elucidation of cardio protective
mechanisms, determined by estrogens and estrogen receptors, will contribute to the development
of effective therapeutic strategies for CVD treatment. | en_US |
dc.publisher | Instituţia Publică Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu” din Republica Moldova | en_US |
dc.relation.ispartof | MedEspera: The 10th International Medical Congress for Students and Young Doctors, 24-27 April 2024, Chișinău, Republic of Moldova | en_US |
dc.subject | estrogen | |
dc.subject | estrogen receptors | |
dc.subject | genomic and non-genomic mechanisms | |
dc.subject | cardiovascular disease | |
dc.title | The role of estrogens in cardiovascular disease | en_US |
dc.type | Other | en_US |
Appears in Collections: | MedEspera 2024
|